AI Article Synopsis
- Patients with cancer, especially those with hematologic malignancies, are considered particularly vulnerable to COVID-19 due to overlapping risk factors.
- Cancer treatments can increase exposure to the virus and weaken patients' natural immune responses.
- Evidence suggests that these individuals should be prioritized for COVID-19 vaccination due to their heightened risk.
Article Abstract
Published series on COVID-19 support the notion that patients with cancer are a particularly vulnerable population. There is a confluence of risk factors between cancer and COVID-19, and cancer care and treatments increase exposure to the virus and may dampen natural immune responses. The available evidence supports the conclusion that patients with cancer, in particular with hematologic malignancies, should be considered among the very high-risk groups for priority COVID-19 vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053003 | PMC |
| http://dx.doi.org/10.1158/2159-8290.CD-20-1817 | DOI Listing |
Publication Analysis
Top Keywords
patients cancer
12
priority covid-19
8
covid-19 vaccination
8
cancer
5
vaccination patients
4
cancer vaccine
4
vaccine supply
4
supply limited
4
limited published
4
published series
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!